THE SCOPE OF THROMBOLYTIC THERAPY AMONG ST SEGMENT ELEVATION MYOCARDIAL INFARCTION IN MISURATA CENTRAL HOSPITAL
Abogurssa, Abdel baset
MetadataShow full item record
Little is known about thrombolytic therapy patterns in patients with ST-elevation myocardial infarction (STEMI) in Libya. The objective of this study is to analyze the use of thrombolytic therapy in patients with ST-Elevation Myocardial Infarction (STEMI) in Misurata Central Hospital. The study includes 73 patients diagnosed with STEMI, from hospital admission to discharge, from a total of 125 patients with acute myocardial infraction admitted to Misurata Central Hospital cardiology care unit between January and December of 2009. RESULTS of the 73 patients with STEMI, 52% (n=38) were thrombolysed with Streptokinase, Alteplase, and Tenecteplase. 14% of eligible STEMI patients did not receive reperfusion therapy. The age of patients varied from 31 to 80 years of age, with a median age of 55.9 years, a majority of 84% being male. The overall median symptom onset- to hospital presentation was 4 hours in thrombolytic recipient patients and 20 hours in non recipient patients. The median door to needle time was 34 minutes. Poor left ventricular ejection fraction was less than 30% and reported more in nonthrombolytic recipient patients. Thrombolytic recipient patients were less likely to develop left ventricular failure. The global in-hospital mortality rate for STEMI patients in 2009 was 8%. Thrombolytic therapy is the only form of reperfusion strategy in Misurata. There was inappropriately long symptom-onset to hospital presentation as well as door- to needle times. Thrombolytic agents improve morbidity but early mortality was relatively high, which needs further exploration.